{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:08:37Z","timestamp":1791133717004,"version":"4.1.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA-16 672"],"award-info":[{"award-number":["CA-16 672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA-124787-01A2"],"award-info":[{"award-number":["CA-124787-01A2"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.bcp.2009.05.027","type":"journal-article","created":{"date-parts":[[2009,5,28]],"date-time":"2009-05-28T04:49:17Z","timestamp":1243486157000},"page":"1083-1094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":143,"title":["Models for prevention and treatment of cancer: Problems vs promises"],"prefix":"10.1016","volume":"78","author":[{"given":"Bharat B.","family":"Aggarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Danda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashasnika","family":"Gehlot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2009.05.027_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2310\/7200.2006.029","article-title":"From ancient medicine to modern medicine: ayurvedic concepts of health and their role in inflammation and cancer","volume":"5","author":"Garodia","year":"2007","journal-title":"J Soc Integr Oncol"},{"key":"10.1016\/j.bcp.2009.05.027_bib2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1126\/science.1166151","article-title":"Cancer. Aneuploidy advantages?","volume":"322","author":"Hernando","year":"2008","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.bcp.2009.05.027_bib3","first-page":"139","article-title":"Chromosomal translocations in cancer","volume":"1786","author":"Nambiar","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2009.05.027_bib4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/ng.f.136","article-title":"Common and rare variants in multifactorial susceptibility to common diseases","volume":"40","author":"Bodmer","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.bcp.2009.05.027_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nrc1299","article-title":"A census of human cancer genes","volume":"4","author":"Futreal","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bcp.2009.05.027_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature05610","article-title":"Patterns of somatic mutation in human cancer genomes","volume":"446","author":"Greenman","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2009.05.027_bib7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.1133427","article-title":"The consensus coding sequences of human breast and colorectal cancers.","volume":"314","author":"Sjoblom","year":"2006","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.bcp.2009.05.027_bib8","doi-asserted-by":"crossref","first-page":"9116","DOI":"10.1158\/0008-5472.CAN-08-2184","article-title":"The role of parental and grandparental epigenetic alterations in familial cancer risk","volume":"68","author":"Fleming","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrc775","article-title":"HeLa cells 50 years on: the good, the bad and the ugly","volume":"2","author":"Masters","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bcp.2009.05.027_bib10","first-page":"4827","article-title":"Evaluation of a soluble tetrazolium\/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines","volume":"48","author":"Scudiero","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1126\/science.275.5298.343","article-title":"An information-intensive approach to the molecular pharmacology of cancer.","volume":"275","author":"Weinstein","year":"1997","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.bcp.2009.05.027_bib12","first-page":"533","article-title":"The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets","volume":"12","author":"Monks","year":"1997","journal-title":"Anticancer Drug Des"},{"key":"10.1016\/j.bcp.2009.05.027_bib13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1470-2045(01)00450-8","article-title":"The use of dubious cell lines in research: is trust enough?","volume":"2","author":"Arlett","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bcp.2009.05.027_bib14","first-page":"5660","article-title":"Cross-contamination of human esophageal squamous carcinoma cell lines detected by DNA fingerprint analysis","volume":"48","author":"van Helden","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib15","first-page":"325","article-title":"Merkel cell carcinoma: a case report","volume":"50","author":"Pathak","year":"2007","journal-title":"Indian J Pathol Microbiol"},{"key":"10.1016\/j.bcp.2009.05.027_bib16","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1126\/science.6451928","article-title":"Cross-contamination of cells in culture","volume":"212","author":"Nelson-Rees","year":"1981","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.bcp.2009.05.027_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1126\/science.7209521","article-title":"Malignant potential of murine stromal cells after transplantation of human tumors into nude mice","volume":"212","author":"Goldenberg","year":"1981","journal-title":"Science (New York, NY)"},{"issue":"3","key":"10.1016\/j.bcp.2009.05.027_bib18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00280-008-0776-9","article-title":"MDA-MB-435 cells are from melanoma, not from breast cancer","volume":"63","author":"Lacroix","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.027_bib19","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/bjc.1997.524","article-title":"Can cancer cells transform normal host cells into malignant cells?","volume":"76","author":"Pathak","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bcp.2009.05.027_bib20","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.4161\/cbt.213","article-title":"Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved","volume":"2","author":"Kerbel","year":"2003","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.bcp.2009.05.027_bib21","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.ejca.2003.11.028","article-title":"Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development","volume":"40","author":"Kelland","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bcp.2009.05.027_bib22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1006\/scbi.2001.0368","article-title":"Mouse models for human familial adenomatous polyposis","volume":"11","author":"Kucherlapati","year":"2001","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.bcp.2009.05.027_bib23","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/1541-7786.MCR-07-2167","article-title":"Zebrafish as a cancer model","volume":"6","author":"Feitsma","year":"2008","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib24","first-page":"191","article-title":"Practices and pitfalls of mouse cancer models in drug discovery","volume":"96","author":"Kung","year":"2007","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib25","first-page":"1531","article-title":"Development of invasive tumors in the \u201cnude\u201d mouse after injection of cultured human melanoma cells","volume":"48","author":"Giovanella","year":"1972","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bcp.2009.05.027_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1054-3589(08)60263-X","article-title":"Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976\u20131982, and future directions","volume":"20","author":"Venditti","year":"1984","journal-title":"Adv Pharmacol Chemother"},{"key":"10.1016\/j.bcp.2009.05.027_bib27","first-page":"1079","article-title":"There are no bad anticancer agents, only bad clinical trial designs\u2014twenty-first Richard and Hinda Rosenthal Foundation Award Lecture","volume":"4","author":"Von Hoff","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib28","doi-asserted-by":"crossref","first-page":"6967","DOI":"10.1073\/pnas.102172399","article-title":"Initiating oncogenic event determines gene-expression patterns of human breast cancer models","volume":"99","author":"Desai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bcp.2009.05.027_bib29","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1158\/0008-5472.CAN-06-3637","article-title":"Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model","volume":"67","author":"Isayeva","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib30","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0378-4274(99)00213-1","article-title":"Use of transgenic mice in identifying chemopreventive agents","volume":"112\u2013113","author":"Alexander","year":"2000","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.bcp.2009.05.027_bib31","first-page":"3949","article-title":"Chemoprevention of spontaneous tumorigenesis in p53-knockout mice","volume":"55","author":"Hursting","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib32","doi-asserted-by":"crossref","first-page":"2404S","DOI":"10.1093\/jn\/133.7.2404S","article-title":"The use of genetically altered mice for breast cancer prevention studies","volume":"133","author":"Kavanaugh","year":"2003","journal-title":"J Nutr"},{"key":"10.1016\/j.bcp.2009.05.027_bib33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1749-6632.1999.tb08719.x","article-title":"Preclinical mouse models for cancer chemoprevention studies","volume":"889","author":"Lipkin","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bcp.2009.05.027_bib34","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ejca.2004.01.009","article-title":"Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery","volume":"40","author":"Fiebig","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bcp.2009.05.027_bib35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2217\/14796694.2.2.201","article-title":"What do, can and should we learn from models to evaluate potential anticancer agents?","volume":"2","author":"Burchill","year":"2006","journal-title":"Future Oncol"},{"key":"10.1016\/j.bcp.2009.05.027_bib36","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/jnci\/djn351","article-title":"Antitumor efficacy testing in rodents","volume":"100","author":"Hollingshead","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bcp.2009.05.027_bib37","first-page":"4227","article-title":"Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models","volume":"9","author":"Voskoglou-Nomikos","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib38","first-page":"226","article-title":"First dose of potential new medicines to humans: how animals help","volume":"3","author":"Greaves","year":"2004","journal-title":"Nat Rev"},{"key":"10.1016\/j.bcp.2009.05.027_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cpt19701113","article-title":"The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man","volume":"11","author":"Schein","year":"1970","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bcp.2009.05.027_bib40","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/rtph.2000.1399","article-title":"Concordance of the toxicity of pharmaceuticals in humans and in animals","volume":"32","author":"Olson","year":"2000","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.027_bib41","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S1470-2045(01)00560-5","article-title":"Trends in biomarker research for cancer detection","volume":"2","author":"Srinivas","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bcp.2009.05.027_bib42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/jnci\/djn482","article-title":"Urine biomarkers may someday detect even distant tumors","volume":"101","author":"Schmidt","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bcp.2009.05.027_bib43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ctrv.2007.09.003","article-title":"New developments in multitargeted therapy for patients with solid tumours","volume":"34","author":"Le Tourneau","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bcp.2009.05.027_bib44","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2009.05.027_bib45","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000113016","article-title":"Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting","volume":"72","author":"Douillard","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.bcp.2009.05.027_bib46","first-page":"476","article-title":"EGFR inhibitors in the treatment of lung cancer","volume":"30","author":"Hirsch","year":"2007","journal-title":"Onkologie"},{"key":"10.1016\/j.bcp.2009.05.027_bib47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.2005.01.5388","article-title":"Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer","volume":"24","author":"Jubb","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2009.05.027_bib48","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/01.coc.0000258732.80710.05","article-title":"Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer","volume":"30","author":"Bukowski","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.bcp.2009.05.027_bib49","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.bcp.2009.05.027_bib50","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1126\/science.1164368","article-title":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","volume":"321","author":"Jones","year":"2008","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.bcp.2009.05.027_bib51","first-page":"99","article-title":"The intestinal stem cell niche studied through conditional transgenesis","author":"Clarke","year":"2006","journal-title":"Ernst Schering Found. Symp Proc"},{"key":"10.1016\/j.bcp.2009.05.027_bib52","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMra061808","article-title":"Cancer stem cells","volume":"355","author":"Jordan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2009.05.027_bib53","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/jnci\/djn168","article-title":"Lapatinib study supports cancer stem cell hypothesis, encourages industry research","volume":"100","author":"Schmidt","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bcp.2009.05.027_bib54","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nature07567","article-title":"Efficient tumour formation by single human melanoma cells","volume":"456","author":"Quintana","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2009.05.027_bib55","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V95.3.952.003k27_952_958","article-title":"Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors","volume":"95","author":"Peichev","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2009.05.027_bib56","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.stem.2007.06.002","article-title":"Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer","volume":"1","author":"Hermann","year":"2007","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bcp.2009.05.027_bib57","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.stem.2007.08.012","article-title":"Cancer stem cells and tumor metastasis: first steps into uncharted territory","volume":"1","author":"Dalerba","year":"2007","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bcp.2009.05.027_bib58","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1158\/0008-5472.CAN-07-5480","article-title":"Cancer stem cells contribute to cisplatin resistance in Brca1\/p53-mediated mouse mammary tumors","volume":"68","author":"Shafee","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib59","first-page":"8","article-title":"FDA proposes new rules for off-label use of prescription drugs. Food and Drug Administration","author":"Baker","year":"1998","journal-title":"Beta"},{"key":"10.1016\/j.bcp.2009.05.027_bib60","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.tips.2005.02.007","article-title":"The efficiency of multi-target drugs: the network approach might help drug design","volume":"26","author":"Csermely","year":"2005","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bcp.2009.05.027_bib61","first-page":"71","article-title":"Multicomponent therapeutics for networked systems","volume":"4","author":"Keith","year":"2005","journal-title":"Nature reviews"},{"key":"10.1016\/j.bcp.2009.05.027_bib62","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJMe0809343","article-title":"Targeted therapy for advanced colorectal cancer-more is not always better","volume":"360","author":"Mayer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2009.05.027_bib63","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ejca.2006.02.013","article-title":"Multiple targeted tyrosine kinase inhibition in the clinic, all for one or one for all?","volume":"42","author":"de Jonge","year":"2006","journal-title":"Eur J Cancer"},{"issue":"Suppl. 10","key":"10.1016\/j.bcp.2009.05.027_bib64","doi-asserted-by":"crossref","first-page":"x1","DOI":"10.1093\/annonc\/mdm407","article-title":"Introduction to \u2018A multitargeted approach: clinical advances in the treatment of solid tumours\u2019","volume":"18","author":"George","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bcp.2009.05.027_bib65","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.1073\/pnas.1337088100","article-title":"Systematic discovery of multicomponent therapeutics","volume":"100","author":"Borisy","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bcp.2009.05.027_bib66","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-target therapeutics: when the whole is greater than the sum of the parts","volume":"12","author":"Zimmermann","year":"2007","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bcp.2009.05.027_bib67","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.tips.2008.11.002","article-title":"Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets","volume":"30","author":"Aggarwal","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bcp.2009.05.027_bib68","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.4161\/cc.7.8.5740","article-title":"Resveratrol: a multitargeted agent for age-associated chronic diseases","volume":"7","author":"Harikumar","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bcp.2009.05.027_bib69","first-page":"3647","article-title":"The guggul for chronic diseases: ancient medicine, modern targets","volume":"28","author":"Shishodia","year":"2008","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib70","first-page":"4457","article-title":"Anticancer potential of silymarin: from bench to bed side","volume":"26","author":"Agarwal","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib71","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ccr.2008.08.006","article-title":"Redefining the target again: chemotherapeutics as vascular disrupting agents?","volume":"14","author":"Gokmen-Polar","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2009.05.027_bib72","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2009.05.027_bib73","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/7410","article-title":"Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB","volume":"5","author":"Wang","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2009.05.027_bib74","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1158\/1535-7163.MCT-08-0715","article-title":"Combination of antiangiogenesis with chemotherapy for more effective cancer treatment","volume":"7","author":"Ma","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bcp.2009.05.027_bib75","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ccr.2008.08.001","article-title":"Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents","volume":"14","author":"Shaked","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2009.05.027_bib76","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/jcb.21500","article-title":"Targeting cell signaling pathways for drug discovery: an old lock needs a new key","volume":"102","author":"Aggarwal","year":"2007","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.bcp.2009.05.027_bib77","first-page":"391","article-title":"High-throughput kinase profiling as a platform for drug discovery","volume":"7","author":"Goldstein","year":"2008","journal-title":"Nat Rev"},{"key":"10.1016\/j.bcp.2009.05.027_bib78","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/0012-1606(65)90005-9","article-title":"The stimulation of epidermal proliferation by a specific protein (EGF)","volume":"12","author":"Cohen","year":"1965","journal-title":"Dev Biol"},{"key":"10.1016\/j.bcp.2009.05.027_bib79","first-page":"1002","article-title":"Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies","volume":"44","author":"Masui","year":"1984","journal-title":"Cancer Res"},{"issue":"Suppl. 6","key":"10.1016\/j.bcp.2009.05.027_bib80","doi-asserted-by":"crossref","first-page":"vi35","DOI":"10.1093\/annonc\/mdm222","article-title":"Erlotinib in cancer treatment","volume":"18","author":"Bareschino","year":"2007","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.bcp.2009.05.027_bib81","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jnci\/djh126","article-title":"Re: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors","volume":"96","author":"Campiglio","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bcp.2009.05.027_bib82","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-07-0507","article-title":"The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells","volume":"6","author":"Krol","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bcp.2009.05.027_bib83","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/JTO.0b013e318168c815","article-title":"Second-line treatment of advanced non-small cell lung cancer","volume":"3","author":"Gridelli","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bcp.2009.05.027_bib84","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2009.05.027_bib85","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1158\/1535-7163.MCT-06-0514","article-title":"Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity","volume":"6","author":"Yamasaki","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bcp.2009.05.027_bib86","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2009.05.027_bib87","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.1158\/0008-5472.CAN-04-0562","article-title":"Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor","volume":"64","author":"Huang","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib88","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.critrevonc.2007.07.002","article-title":"Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety","volume":"66","author":"Lazaridis","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bcp.2009.05.027_bib89","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1158\/1535-7163.MCT-06-0423","article-title":"Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling","volume":"6","author":"Nahta","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bcp.2009.05.027_bib90","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/1535-7163.MCT-06-0766","article-title":"Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance","volume":"6","author":"Barok","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bcp.2009.05.027_bib91","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2009.05.027_bib92","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/416279b","article-title":"Tumour biology: herceptin acts as an anti-angiogenic cocktail","volume":"416","author":"Izumi","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2009.05.027_bib93","first-page":"5345","article-title":"Amplification of HER-2\/neu and topoisomerase IIalpha in primary and metastatic breast cancer","volume":"61","author":"Tanner","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib94","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3816\/CBC.2002.n.028","article-title":"Resistance to trastuzumab: a necessary evil or a temporary challenge?","volume":"3","author":"Cardoso","year":"2002","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.bcp.2009.05.027_bib95","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1158\/0008-5472.CAN-03-3900","article-title":"P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells","volume":"64","author":"Nahta","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib96","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2009.05.027_bib97","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-04-0225","article-title":"Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2","volume":"10","author":"Gennari","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib98","doi-asserted-by":"crossref","first-page":"11991","DOI":"10.1158\/0008-5472.CAN-07-2068","article-title":"Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2","volume":"67","author":"Varchetta","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib99","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/cncr.22418","article-title":"Kinetics of serum HER-2\/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy","volume":"109","author":"Mazouni","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2009.05.027_bib100","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2009.05.027_bib101","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/13543784.16.7.1111","article-title":"Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma","volume":"16","author":"Duvic","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.bcp.2009.05.027_bib102","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jsbmb.2007.09.004","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors","volume":"108","author":"Polyzos","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.bcp.2009.05.027_bib103","doi-asserted-by":"crossref","first-page":"747s","DOI":"10.1158\/1078-0432.CCR-06-2063","article-title":"Sorafenib in renal cell carcinoma","volume":"13","author":"Flaherty","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib104","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2009.05.027_bib105","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2005.10.017","article-title":"Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer","volume":"23","author":"Hurwitz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2009.05.027_bib106","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.clinthera.2006.11.015","article-title":"Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies","volume":"28","author":"Shih","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.bcp.2009.05.027_bib107","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/annonc\/mdi247","article-title":"Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors","volume":"16","author":"Holden","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bcp.2009.05.027_bib108","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1200\/JCO.2005.01.9661","article-title":"Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer","volume":"23","author":"Kindler","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2009.05.027_bib109","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","article-title":"Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab","volume":"91","author":"Scappaticci","year":"2005","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.bcp.2009.05.027_bib110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev.med.57.042905.122625","article-title":"Bortezomib: proteasome inhibition as an effective anticancer therapy","volume":"57","author":"Richardson","year":"2006","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.bcp.2009.05.027_bib111","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev.pharmtox.46.120604.141300","article-title":"The proteasome and proteasome inhibitors in cancer therapy","volume":"46","author":"Voorhees","year":"2006","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.bcp.2009.05.027_bib112","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2009.05.027_bib113","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa0808268","article-title":"Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer","volume":"360","author":"Tol","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2009.05.027_bib114","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-3-540-69297-3_17","article-title":"Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention","volume":"181","author":"Dunn","year":"2009","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib115","doi-asserted-by":"crossref","first-page":"7250","DOI":"10.1158\/0008-5472.CAN-08-1374","article-title":"On the eve of personalized medicine in oncology","volume":"68","author":"Yeatman","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib116","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.clpt.6100204","article-title":"Personalized medicine: elusive dream or imminent reality?","volume":"81","author":"Lesko","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bcp.2009.05.027_bib117","doi-asserted-by":"crossref","first-page":"7988","DOI":"10.1158\/1078-0432.CCR-08-1211","article-title":"Advances in breast cancer: pathways to personalized medicine","volume":"14","author":"Olopade","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib118","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/cncr.22966","article-title":"Getting to personalized cancer medicine: taking out the garbage","volume":"110","author":"Compton","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2009.05.027_bib119","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1158\/1541-7786.MCR-08-0435","article-title":"Rembrandt: helping personalized medicine become a reality through integrative translational research","volume":"7","author":"Madhavan","year":"2009","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.bcp.2009.05.027_bib120","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","article-title":"Off-label prescribing among office-based physicians","volume":"166","author":"Radley","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.bcp.2009.05.027_bib121","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/S1470-2045(08)70280-8","article-title":"Off-label use of anticancer drugs","volume":"9","author":"Leveque","year":"2008","journal-title":"Lancet Oncol"},{"issue":"53","key":"10.1016\/j.bcp.2009.05.027_bib122","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.surneu.2007.06.029","article-title":"The effect of bevacizumab (Avastin) on neuroimaging of brain metastases","volume":"70","author":"Mathews","year":"2008","journal-title":"Surg Neurol"},{"key":"10.1016\/j.bcp.2009.05.027_bib123","first-page":"72","article-title":"Novel genomic methods for drug discovery and mechanism-based toxicological assessment","volume":"12","author":"Gant","year":"2009","journal-title":"Curr Opin Drug Discov Dev"},{"issue":"May (5)","key":"10.1016\/j.bcp.2009.05.027_bib124","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin Proc"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295209004328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295209004328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:59:08Z","timestamp":1777377548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295209004328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":124,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0006295209004328"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2009.05.027","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Models for prevention and treatment of cancer: Problems vs promises","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2009.05.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}